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SUMMARY
To evaluate the alibration of a disease risk predition tool, the quantity E/O, i.e., the ratio of the
expeted number of events to the observed number of events, is generally omputed. However, beause
of ensoring, or more preisely beause of individuals who drop out before the termination of the study,
this quantity is generally unavailable for the omplete population study and an alternative estimate
has to be omputed. In this paper, we present and ompare four methods to do this. We show that two
of the most ommonly used methods generally lead to biased estimates. Our arguments are rst based
on some theoreti onsiderations. Then, we perform a simulation study to highlight the magnitude of
the previously mentioned biases. As a onluding example, we evaluate the alibration of an existing
preditive model for breast aner on the E3N-EPIC ohort.
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1. INTRODUCTION
Researhers, physiians, as well as the general publi, are fousing inreasingly on statistial
models designed to predit the ourrene of a disease. The rst orresponding model  the
Framingham Coronary Risk Predition Model published in 1976 [13℄  was aimed at prediting
the individual's risk of developing heart disease. Modied versions of this primary model are
now widely used by physiians to make deisions on prevention and treatment strategies. From
the late 1980's, researhers published predition models for the absolute risk of breast aner
[2℄, [8℄, [16℄, and some predition tools dealing with other types of aner have begun to appear
in the literature over reent years [1℄, [17℄. In a workshop held in 2005, Freedman et al. [7℄
already pointed out the growth of both the number of aner risk predition tools and the
need to ensure that they are rigorously evaluated.
Two main riteria, disrimination and alibration, are usually retained for evaluation.
Other riteria may be retained for partiular purposes, see [9℄ for some relevant examples.
Disrimination measures the ability to segregate the individuals into two groups, those who will
develop the disease, and those who will not. It is often evaluated by the onordane statisti,
whih is also the area under a reeiver operating harateristi (ROC) urve. Calibration 
our onern here  measures the ability to predit the number of events in the population
of interest S, usually over a t0-year period, t0 > 0: it measures the goodness-of-t of the
model. Calibration is ommonly evaluated by omparing the observed number of events with
the number of events expeted to our within the t0-year period [14℄, [15℄. By summing the
estimated t0-year risks over all individuals belonging to a given representative sample Sn of
the population S, we get the expeted number of ases E. Considering in its turn the number
O of ases observed in Sn over the t0-year period, the E/O ratio provides an estimator of the
theoretial quantity E/O that would be obtained by evaluating the onsidered model on the
whole population S, assumed to be innite (in this asymptoti setting, E and O would stand
for rates rather than numbers). A well alibrated model on S would have a theoreti E/O
equalling 1. Thus, the E/O ratio is usually statistially ompared to one to denitely assess
the model alibration.
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However, due to either administrative reasons (the patient was followed until the end of the
study but did not develop the disease by that date) or the dropping out phenomenon (inluding
both "pure" loss of follow-up and death for reasons other than the onsidered disease) data
are ensored in most epidemiologi studies. This implies that the t0-year status regarding the
disease is unknown for some individuals, and that the only available information for these
individuals is that they did not develop the disease after z years of follow-up, with 0 < z < t0.
In other words, the number of ases whih would have ourred in the population Sn over
the t0-year period is unknown, beause of the individuals who dropped out before t0 years of
follow-up. To get round this issue, various methods have been proposed and applied to provide
estimators alternative to the unobserved E/O ratio. However, as will be shown later, most of
these methods generally lead to biased estimates. In the following Setion 2, we provide the
derivation of four methods. For eah of them we explain its priniple as well as its potential
inauray from a theoretial point of view. The ondene bands assoiated with eah method
are also presented. Then, in Setion 3, a omparison between the four methods is performed
on simulated data. Finally we ompare these methods on a real sample, the E3N-EPIC ohort,
in whih we evaluate one of the Nurses Health Study based breast aner predition tools [16℄
(see Setion 4). These examples support our assertion that two most ommonly used methods
lead to potentially highly biased estimates.
2. METHODS
2.1. Notations
Some notations will be of partiular interest to desribe the various methods that have been
(or an be) used to evaluate alibration.
Let Y be the random variable of interest (in most ases, Y will stand for the delay between
the inlusion in the study and the ourrene of the onsidered disease), and C the ensoring
variable. The observed variables will be denoted by Z = min(Y,C) and δ = 1I{Y ≤ C},
where 1IS equals 1 if the ondition S is true and 0 otherwise (i.e., here, δ equals 1 if Y ≤ C,
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and 0 otherwise). We x t0 > 0 and onsider the evaluation of a t0-year risk predition tool
Pt0 on a given population S. Assume a representative sample Sn = {1, ..., n} ⊂ S, n ≥ 1, is
at our disposal. In this setting, our aim is to estimate the theoretial E/O ratio (relative to
Pt0 on S) on the sample Sn. For every individual i ∈ Sn, denote by zi his observed time of
follow-up, and ei = ei(t0) his expeted risk aording to Pt0 . Throughout, we will assume that
t0 ≤ maxi∈Sn zi. Further introdue the random variable Oi = 1I{Yi ≤ t0} (i.e., Oi equals one
if Yi ≤ t0 and 0 otherwise), and set oi for the realisation of Oi, i = 1, ..., n.
We will denote by Sn,ks the group onsisting of individuals for whom the status regarding
the disease after t0 years of follow-up is known. They will be referred to hereafter as 'known
t0-status individuals'. This group onsists of
1. individuals who developed the disease before t0 years of follow-up (yi ≤ ci, zi ≤ t0 and
oi = 1 for these individuals);
2. individuals who developed the disease after t0 years of follow-up (yi ≤ ci, zi ≥ t0 and
oi = 0 for these individuals);
3. individuals who did not develop the disease and were followed-up at least t0 years (ci ≤ yi,
zi ≥ t0 and oi = 0 for these individuals).
Here and elsewhere, yi [resp. ci℄ stands for the realisation of the random variable Yi [resp. Ci℄.
Similarly, we will denote by Sn,uks the group onsisting of individuals for whom the status is
unknown: for these 'unknown t0-status individuals', ci ≤ yi, zi ≤ t0, so Oi is unobserved and
oi is unknown.
Note that the rate of unknown t0-status individuals inreases as t0 inreases. Therefore, the
size of Sn,uks relatively to that of Sn,ks inreases as t0 inreases. In addition, Sn,ks as well as
Sn,uks are unrepresentative with respet to the whole population Sn, as generally,
IP(Yi ≤ t0|i ∈ Sn,ks) 6= IP(Yi ≤ t0|i ∈ Sn)
and IP(Yi ≤ t0|i ∈ Sn,uks) 6= IP(Yi ≤ t0|i ∈ Sn). (1)
More preisely, one an see that Sn,ks overrepresents ases with respet to Sn, i.e.,
IP(Yi ≤ t0|i ∈ Sn,ks) ≥ IP(Yi ≤ t0|i ∈ Sn). (2)
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This is the main reason why, to derive inferene on S in the presene of ensoring, typial tools
(e.g., the Kaplan-Meier estimate when estimating the unonditional probability of developing
the disease) are required to ensure unbiased estimates.
Before presenting the four methods aimed at evaluating the alibration of Pt0 on S, some
additional notations are needed. Denote by n
ks
[resp. n
uks
℄ the number of individuals belonging
to Sn,ks [resp. Sn,uks℄. Obviously, we have n = nks + nuks (sine Sn,ks ∪ Sn,uks = Sn and
Sn,ks∩Sn,uks = ∅). The following quantities will be of partiular interest in the sequel. Introdue
ESn =
∑
i∈Sn
ei; ESn,ks =
∑
i∈Sn,ks
ei; ESn,uks =
∑
i∈Sn,uks
ei;
OSn =
∑
i∈Sn
Oi; OSn,ks =
∑
i∈Sn,ks
Oi; OSn,uks =
∑
i∈Sn,uks
Oi.
Note that the "O" terms are random and possibly unobserved (in partiular, OSn and OSn,uks
are unobserved) whereas the "E" terms are non-random and known. This is lassial in
evaluation studies where inferene is made given the sample, whih ensures that ei is non-
random for i = 1, ..., n.
Sine OSn is unobserved, ESn/OSn annot be used to estimate the theoretial E/O ratio. We
present four methods to get round this issue in the following paragraphs.
2.2. Method M0
In some validation studies [14℄,[15℄, the evaluation of the alibration is restrited to Sn,ks, and
the quantity E/O is estimated by
R0,n = ESn,ks/OSn,ks . (3)
However, in view of (1)−(2), if a model has to be evaluated on Sn, a lot of attention has to be
paid when the validation is performed on Sn,ks: if the sore is well alibrated on S (and then
on Sn), then the expetation of the ESn,ks/OSn,ks ratio does not equal 1. In fat, it an even be
shown that this expetation is less than 1, sine the known t0-status group Sn,ks overrepresents
ases with respet to Sn and S (see (2) above and (11) below).
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2.3. Method M1
Another method, evaluating the alibration on the whole population Sn, an be found in
the literature (see, for instane, [3℄). The underlying idea is that although OSn is not at our
disposal, O1,Sn =
∑
i∈Sn
1I{Yi ≤ min(zi, t0)} is. Then, setting
E1,Sn =
∑
i∈Sn
ei(min(t0, zi)), (4)
the estimate of E/O is omputed as follows
R1,n = E1,Sn/O1,Sn = E1,Sn/OSn,ks . (5)
Note that ei(min(t0, zi)) = ei(t0) only for individuals i who were still disease-free after t0
years. For all other individuals (i.e., the individuals belonging to Sn,uks, plus the individuals
belonging to Sn,ks for whom oi = 1), we have ei(min(t0, zi)) = ei(zi) ≤ ei(t0).
To see why this method is inappropriate, we present a simple example. Assume a database
of 10,000 individuals followed over a 5-year period (with no dropping-out) is at our disposal.
Further suppose that the risk of the onsidered disease is uniform over the 5-year period,
suh that IP(Y ≤ t) = t/100, for all t ≤ 5. Then about 100 ases are likely to be observed
eah year. Assume 100 ases are observed eah year (giving 500 ases observed overall) and
the evaluation of the predition tool Pt = t/100, for all t ≤ 5, is under study. All the 9,500
individuals who remained free from disease after the 5-year period ontribute to 5% in the
alulus of E1,Sn . On the other hand, all the individuals who developed the disease within the
rst year of follow-up ontribute to (at most) 1%, those who developed the disease within the
seond year of follow-up to 2%, and so on. Therefore, aording toM1, the number of expeted
ases is (at most)
100× 1% + 100× 2%+ 100× 3%+ 100× 4%+ 100× 5%+ 9, 500× 5% = 490,
in suh a way that R1,n = 0.98! Obviously, the bias is more severe when the disease prevalene
is high.
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2.4. Method M2
An easy way to orret the aforementioned bias pertaining toM1 exists. In fat, OSn,ks is known
and only OSn,uks is unknown. Following the idea of M1, however, O1,Sn,uks =
∑
i∈Sn,uks
1I{Yi ≤
min(zi, t0)}(=
∑
i∈Sn,uks
1I{Yi ≤ zi} = 0), and thus, O2,Sn = OSn,ks + O1,Sn,uks are known.
Therefore, setting
E2,Sn =
∑
i∈Sn,ks
ei(t0) +
∑
i∈Sn,uks
ei(zi), (6)
a new estimate of E/O is given by
R2,n = E2,Sn/O2,Sn = E2,Sn/OSn,ks . (7)
Conretely, in (6), the individuals who developed the disease before t0 years of follow-up
ontribute to ei(t0) while they ontribute to ei(zi) in (4) (keep in mind that ei(zi) ≤ ei(t0)
beause zi ≤ t0 for suh individuals). Comparing the estimates provided by M1 and M2, it is
easily derived that
C1(t0) =
R2,n
R1,n
= 1 +
∑
i∈Sn,ks
δi{ei(t0)− ei(zi)}
OSn,ks
≥ 1. (8)
Note that, to our knowledge,M2 has never been used so far, although it provides a simple and
pratial way to improve M1. However, it is not lear whether R2,n is unbiased or not: the
expliit expression of the expetation of R2,n (or 1/R2,n) an not be easily derived. Moreover,
there exists a drawbak ommon to both M1 and M2: using either method, the evaluation
of a rude t0-year risk sore an not be performed. In fat, some of the ei's involved in the
alulation of E1,Sn and E2,Sn are attahed to a t0-year period, while others are attahed
to a zi-year period. The main problem arises when alibration is adjusted for perentiles of
predited risk (whih is quite ommon in evaluation studies), and is due to the fat that the
ei's are not omparable. In this adjusted setting, the estimation of the ei's distribution, and
then the derivation of their perentiles, beomes hazardous. Similar problems also arise when
alibration is adjusted for risk fators (suh as age at inlusion or personal history of the
disease). Therefore, M2 should not be used when adjusted alibration has to be evaluated.
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2.5. The method M3
Keep in mind that in the absene of dropping-out, the quantity ESn/OSn provides a suitable
estimate of E/O. The problem in the presene of dropping-out arises from the fat that OSn
is unknown. However, a natural andidate to replae OSn is dened as follows,
ÔSn = nKn(t0), (9)
where Kn(t0) is the Kaplan-Meier estimate of IP(Y ≤ t0) on Sn. Using this [4℄, an estimate of
E/O an be given by
R3,n =
ESn
ÔSn
· (10)
Note that sine Kn(t0)→ IP(Y ≤ t0) almost surely as n→∞, for any t0 ≤ maxi∈Sn zi [18℄, it
is easily derived that R3,n is asymptotially unbiased.
Through this theoretial desription of the various methods, we showed that R0,n and R1,n
provide biased estimates. Moreover, the asymptoti unbiasedness was established for R3,n but
not forR2,n, suggesting thatR3,n is the most reliable estimate of the E/O ratio. Moreover,R3,n
is intuitively the most appealing estimator beause it takes into aount all the information
available after t0 years of follow-up. These statements will be onrmed by the simulation
studies performed in Setion 3.
2.6. Some omplements
Some additional properties of the various methods merit presentation.
2.6.1. The inadmissibility of M0 Comparing R0,n and R3,n gives insight into the magnitude
of the bias pertaining to M0. Under the assumption of independene between the vetor of
ovariates and the ensoring variable, it an be shown that
C0(t0) =
R3,n
R0,n
=
ESn/ÔSn
ESn,ks/OSn,ks
≈
Fn
ks
(t0)
Kn(t0)
= C˜0(t0), (11)
where Fn
ks
(t0) is the empirial distribution funtion on Sn,ks, i.e., the standard estimate of the
probability of developing the disease on Sn,ks. See Appendix for the proof of (11).
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Sine Kn(t0) ≤ Fn
ks
(t0), almost surely for n large enough, we have C0(t0) ≥ 1. For instane,
set Z = maxi∈Sn zi, and selet t0 = Z. In this partiular example, all the ases belong to
Sn,ks; non-ases do not. Thus, Fn
ks
(Z) = 1, while Kn(Z) ≪ 1 (typially, Kn(Z) does not
exeed 0.2), and C0(Z) beomes high. Even if this ase is somewhat extreme, it highlights the
inadmissibility of M0, whih is however among the most widely used of methods.
2.6.2. Condene intervals In order to onlude whether a given predition tool is well
alibrated on S or not, ondene intervals are generally needed. When the estimation of
E/O is based on M0, M1 or M2, suh intervals an be alulated using the Poisson variane
for the logarithm of the observed number of ases [15℄. Namely, for j = 0, 1, 2,
CIj,n,95%(E/O) =
[
Rj,n exp
(
± 1.96
√
1/OSn,ks
)]
. (12)
Note that, sine M0 and M1 lead to biased estimates of the quantity E/O, the above formula
may only be orret for j = 2 (if, eventually, R2,nturns out to be unbiased).
On the other hand, in the ase of M3, a log-transformation an be oupled with the delta-
method, giving
Var
[
log
(ESn
ÔSn
)]
=
σ2n,t0
K2n(t0)
,
where σ2n,t0 is the Greenwood variane [12℄ of the Kaplan-Meier estimate evaluated at t0. The
orresponding ondene interval is given by
CI3,n,95%(E/O) =
[
R3,n exp
(
± 1.96
σn,t0
Kn(t0)
)]
· (13)
3. SIMULATION STUDY
A simulation study was performed to hek that R2,n and R3,n were better estimates of the
E/O ratio than R1,n and R0,n, and to ompare R2,n and R3,n.
We onsidered the ase where Y  U(0, λ), for a given λ > t0, i.e., Y was uniformly distributed
on the interval [0, λ]. This ensured that IP(Y ≤ t) = t/λ, for all 0 ≤ t ≤ λ. Note that the higher
the rate 1/λ, the higher the prevalene of the disease, and therefore, the higher the bias of
R1,n is expeted to be (see Setion 2.3). For the ensoring variable, we hose C  U(0, ωλ),
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for a given ωλ > 0. To allow the rate of unknown t0-status individuals to vary, we seleted
various values of ωλ, depending on the rate 1/λ. We also onsidered the ase with no ensure
(and therefore with no unknown t0-status individuals) to hek that M0, M2 andM3 provided
the same estimates in this ase.
Given n ≥ 1, samples (Y1, ..., Yn) and, if appropriate, (C1, ..., Cn) were simulated. From
these samples, we generated the observed sample ((Z1, δ1), ...(Zn, δn)), where, as usual,
Zi = min(Yi, Ci) and δi = 1I{Yi ≤ Ci}. The population Sn = {1, ..., n} ould then be split into
Sn,ks and Sn,uks, making the alulation of OSn,ks and OSn,uks possible. Moreover, the Kaplan-
Meier estimate ould be alulated on our samples, enabling us to ompute ÔSn . Finally, the
terms ESn , ESn,ks , E1,Sn and E2,Sn , and then R0,n, R1,n, R2,n and R3,n, were omputed
using the formula ei(t0) = t0/λ and ei(zi) = zi/λ, and the orresponding ondene intervals
were onstruted making use equations (12) and (13). Note that, given the way the expeted
number of ases was alulated, the underlying predition tool should be well alibrated, and
Rj,n should be lose to one if the method Mj, j = 0, 1, 2, 3, provided unbiased estimates of
the E/O ratio.
In every example, we seleted n = 20, 000 and t0 = 10. We repeated the proedure desribed
above 1,000 times, omputing (i) the mean for eah of the Rj,n, j = 0, 1, 2, 3, (ii) the mean
width of the orresponding ondene interval and (iii) the proportion of ondene intervals
inluding the value 1 (whih is an estimate of the overing probability of the ondene
interval).
We seleted λ = 100, λ = 200 and λ = 400, and in eah ase, we seleted three values of ωλ
suh that there was 5%, 10% and 20% of unknown 10-year status individuals (plus the ase
with no ensure at all): this resulted in 3×4 = 12 simulation designs. The results are presented
in Table I.
First onsider the mean of the point estimates obtained for eah method in eah simulation
design. We observed that the estimates R0,n, R2,n and R3,n were idential in the unensored
ases, orresponding to the ases where the rate of unknown t0-status individuals was null. In
addition, we observed that R1,n < 1 in every ase, and that the bias magnitude depended upon
Prepared using simauth.ls
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the "prevalene" 1/λ, independently of the rate of unknown t0-status individuals. Finally, the
error made when using R0,n was all the higher as this rate inreased (as expeted again).
All these observations onrmed the assertions presented in Setion 2. The orreting terms
presented in Table II made these observations even learer and supported the approximation
stated in (11). Furthermore, the estimates R2,n and R3,n gave very similar values, whih
were lose to the true value 1. These rst results onrmed the fat that R2,n and R3,n were
better estimates of the E/O ratio than R0,n and R1,n, and then that the use of the latter two
estimators should be avoided.
Considering in more detail R2,n and R3,n, we saw that the means of the R3,n's were slightly
loser to 1 that those of the R2,n's. Moreover, by omparing the width and the overing
probability of the orresponding ondene interval, R3,n appeared to be more preise than
R2,n, with narrower but still more aurate ondene intervals. Therefore, from this simple
simulation study, the estimate R3,n turned out to be the most advisable one.
Note that the preision of R3,n (as well as that of R2,n) was losely related to the prevalene
1/λ: the higher the prevalene, the more preise the estimates.
4. CASE STUDY : THE EVALUATION OF AN EXISTING BREAST CANCER
PREDICTION TOOL ON THE E3N COHORT
E3N (Etude Epidémiologique des femmes de l'Eduation Nationale) is the Frenh omponent
of the EPIC (European Prospetive Investigation into Caner and nutrition) prospetive
study and has been thoroughly desribed elsewhere [6℄. All partiipants are women belonging
to the Mutuelle Générale de l'Eduation Nationale (MGEN), a health insurane sheme
primarily overing teahers, teaher's spouses, and employees of the National Eduation
System. Sine June 1990, after having given informed onsent, 98,995 women have been
asked at approximately 24-month intervals to omplete self-administered questionnaires, whih
inlude a variety of lifestyle harateristis. After the exlusion of the prevalent ases of aner
(n=6,999) and women who had never menstruated (n = 28), the ohort inludes 91,968
observations (with 3,467 ases of invasive breast aner).
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Rosner and Colditz models proposed two breast aner risk predition models aording to
whih inidene of breast aner at age a (Ia) is proportional to the number of breast ell
divisions aumulated throughout life up to age a [16℄, [2℄. The rate of breast aner ell
division at age a′ is supposed to be dependent on risk fators that are relevant at age a′.
Rosner and Colditz thus expressed the log inidene rate of breast aner as a linear funtion
of the umulative eet of individual breast aner risk fators. In a rst attempt [16℄, in
addition to age (a), only reprodutive fators were onsidered, namely, age at menarhe (a0),
menopausal status (m), age at menopause (am), parity s, age at rst birth (a1), and a variable
b, alled birth index and dened as b =
∑s
i=1(a
⋆ − ai)bi,a, where ai is the age at ith birth,
a⋆ = min(a, am) and bi,a = 1 if parity is greater than i at age a, 0 otherwise. Dening b1 as 1
if s ≥ 1, 0 otherwise, the RCM was speied as
log Ia = α+ β0a0 + β1(a
⋆ − a0) + β2(a− am)m
+β3(a1 − a0)b1 + β4b+ β5b(a− am)m. (14)
The values of the parameters α, β1, ..., β5 estimated in [16℄ are realled for onveniene in Table
III.
Rosner and Colditz later developed a model inluding more fators [2℄; an evaluation study
of the two versions an be found in Rokhill et al. [15℄. We hose to evaluate the rst version
(RCM) as some of the variables involved in the extended one were not available in the E3N
study (BMI at menarhe, for instane). Moreover, our aim was to measure the respetive
performanes of the methods presented in Setion 2 rather than to evaluate the best published
model.
To ompute the t-year risk (where t an take the value t0 or zi depending on the method to be
used to evaluate the RCM), we proeeded as in Rokhill et al.'s evaluation study [15℄: one we
obtained, from (14), the log inidene rates for eah year for eah woman, we exponentiated
eah one to get an inidene rate rj , j = 1, ..., t, for eah year during the t-year period; then,
the t-year risk was omputed as 1− exp(−[r1 + · · ·+ rt]). We hose t0 = 10 years. In addition,
we performed the evaluation on three groups:
• the whole sample (n = 91, 968);
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• Postmeno. Group 1, omprised of women who were at inlusion (n = 36, 603);
• Postmeno. 2, omprised of Postmeno. Group 1 plus the women who went through the
menopause during the study (these women entered this group at the time of their
menopause) (n = 82, 402).
For the whole sample (n = 91, 968), the rate of unknown t0-status individuals was 12%
(n
ks
= 80, 883), and the Kaplan-Meier estimate of the unonditional risk of disease was
3.21%. For Postmeno. Group 1 (n = 36, 603), the rate of unknown t0-status individuals was
12.5% (n
ks
= 32, 027), and the Kaplan-Meier estimate of the unonditional risk of disease
was 3.39%. For Postmeno. Group 2 (n = 82, 402), the rate of unknown t0-status individuals
was 51.5% (n
ks
= 39, 931), and the Kaplan-Meier estimate of the unonditional risk of disease
was 3.60%. The results presented in Table IV were onsistent with our previous explanations.
The estimates R2,n and R3,n gave similar results, whereas R1,n and espeially R0,n were
slightly dierent and oneivably biased. Moreover, R3,n was more preise than R2,n. Note
that the bias magnitude of R0,n was of the same order as that expeted in view of the results
of the simulation study. In fat, for the whole sample and Postmeno. Group 2, the rate of
unknown t0-status individuals was about 12 %. In our simulation study, we observed that
C˜0(t0) ≃ 1.055 for 10 % of unknown t0-status individuals. Here, we had C0(t0) = 1.065 and
C0(t0) = 1.074 on the whole sample and Postmeno. Group 1 respetively (on Postmeno. Group
2, we had C0(t0) = 1.43, but this feature ould not be ompared with our simulated results,
sine the rate of unknown t0-status individuals reahed 51.5% for this group). However, the
bias magnitude of R1,n was slightly less important than what ould have been expeted from
our simulation study. Indeed, the prevalene of the disease was about 1/300 per year (around
1/30 over 10 years), and we alulated C0(t0) ≃ 1.01, while 1.02 was expeted. This highlights
the fat that the distribution of Y plays an important role with respet to the bias of R1,n.
In fat, this bias is larger for a uniform distribution than, for instane, an exponential one,
where ases are likely to our later (and in whih ase, the terms ei(zi) are likely to be loser
to ei(t0)).
Note that the RCM appeared to slightly underestimate the breast aner risk in the whole
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E3N population. This underestimation was wider for the postmenopausal groups, espeially on
Postmeno. Group 2. The main reason might be that RCM does not take hormone replaement
therapy (HRT) use into aount. HRT is known to inrease the risk of aner [5℄, [6℄. Moreover,
the use of HRT is more and more frequent in the E3N population as well as in the general
population: this means that, overall, the use of HRT is more frequent in Postmeno. Group
2 than in Postmeno. Group 1. Therefore, this ould explain (at least partly) the wider
underestimation observed on Postmeno. Group 2.
5. DISCUSSION
We have presented and ompared four methods aimed at evaluating the alibration of disease
risk predition tools. It was shown that the estimates R3,n and R2,n should be preferred to
R0,n and R1,n, the latter two being biased in most situations. The estimator R3,n appeared
to be more preise than R2,n on simulated data. In addition, the unbiasedness of R2,n was not
theoretially established here, and its appliability was shown to be limited (in partiular, it
should not be used when alibration has to be adjusted for perentiles of predited risks).
Some other more sophistiated riteria (suh as Hosmer and Lomeshow [11℄ goodness-of-t
statistis) may also be retained to evaluate the alibration. Here, we foused on the so-
alled E/O ratio, but the problems arising in this simple ase of ourse still arise when more
sophistiated riteria are used, and we reommend the use of the Kaplan-Meier estimate to
estimate the "O" terms involved in the Hosmer-Lomeshow statisti. If this is done, however, we
also reommend either heking the χ2 distribution of the resulting statisti or using bootstrap
tehniques to derive the assoiated p-value.
The problem of individuals who dropped out before t0 years of follow-up still arises when
evaluating the disrimination of a t0-year risk sore. It has been shown that the onordane
statisti is biased when estimated only on the known t0-status group, and an unbiased estimate
has been proposed when the underlying model is a Cox proportional hazard model with time
under study as the time sale [10℄. In other ases, no unbiased estimates have ever been
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proposed. An alternate approah is to ompute the Observed Relative Risk (ORR). To do this,
individuals have to be sorted by predited t0-year risks. Then, the ORR is simply the ratio of
the number of observed ases in the top deile (or quintile) of predited t0-year risks to the
number of observed ases in the bottom deile (or quintile). Obviously, sine observed numbers
of ases are generally not at the statistiian's disposal, Kaplan-Meier estimates (and bootstrap
ondene intervals) are required in this setting too.
As a onlusion, we strongly reommend the use of R3,n as an estimate of the E/O, even if it
is not the most ommonly used estimate in the evaluation of alibration literature (espeially
in the breast aner eld).
6. APPENDIX
6.1. Proof of (11)
Our aim is rst to prove (11), whih is realled in (15) below for onveniene,
C1(t0) ≈
Fn
ks
(t0)
Kn(t0)
. (15)
First note that
ESn
OSn
=
(ESn,uks + ESn,ks)
OSn,ks
OSn,ks
OSn
=
ESn,ks
OSn,ks
(
1 +
ESn,uks
ESn,ks
)
OSn,ks
OSn
,
where OSn,uks (resp. ESn,uks) is the observed (resp. expeted) number of ases on Sn,uks.
Keeping in mind that OSn,ks = nksFnks(t0), ÔSn = nKn(t0)) and n = nks + nuks, it is
straightforward that
ES
ÔS,n
=
ESn,ks
OSn,ks
(
1 + ESn,uks/ESn,ks
1 + n
uks
/n
ks
)
Fn
ks
(t0)
Kn(t0)
·
Next, introdue the following assumption:
(H) The ensoring proess is independent from the ovariates.
Remark 1. The ondition (H) ensures that the distribution of the ovariates is the same on
Sn,uks and Sn,ks (and then on Sn).
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Under (H), with eˆn = ESn/n,
ESn,uks
ESn,ks
≃
eˆnnuks
eˆnnks
=
n
uks
n
ks
,
in suh a way that
ESn
ÔSn
≃
ESn,ks
OSn,ks
Fn
ks
(t0)
Kn(t0)
· (16)
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Table I. Results of the simulation studies. The mean of the estimate of the E/O ratio, the mean of
the width of the orresponding ondene interval and the proportion of these intervals inluding the
value 1 are given respetively for eah of the four methods in eah of the 12 simulation designs. Means
were obtained from 1,000 independent samples.
Rate of Observed Method Method Method Method
UKSI
‡
Cases M0 M1 M2 M3
Case 1 : λ = 100
0 2,000 1.000 0.088 0.967 0.950 0.083 0.374 1.000 0.088 0.967 1.000 0.083 0.957
5% 1,947 0.976 0.087 0.809 0.951 0.085 0.406 1.001 0.089 0.955 1.001 0.084 0.946
10% 1,895 0.950 0.086 0.391 0.951 0.086 0.410 1.002 0.090 0.967 1.001 0.086 0.961
20% 1,787 0.893 0.083 0.003 0.953 0.088 0.462 1.004 0.093 0.963 1.001 0.088 0.951
Case 2 : λ = 200
0 1,001 1.000 0.124 0.954 0.975 0.121 0.876 1.000 0.124 0.954 1.000 0.121 0.949
5% 973 0.976 0.123 0.891 0.978 0.123 0.891 1.003 0.126 0.960 1.002 0.123 0.953
10% 948 0.949 0.121 0.620 0.976 0.124 0.898 1.002 0.128 0.958 1.001 0.124 0.956
20% 896 0.890 0.117 0.066 0.977 0.128 0.887 1.003 0.132 0.959 1.001 0.128 0.955
Case 3 : λ = 400
0 500 1.002 0.176 0.950 0.990 0.174 0.931 1.002 0.176 0.950 1.002 0.174 0.950
5% 488 0.976 0.174 0.907 0.989 0.176 0.939 1.002 0.178 0.964 1.002 0.181 0.960
10% 475 0.948 0.171 0.783 0.989 0.178 0.942 1.001 0.181 0.968 1.001 0.178 0.964
20% 448 0.893 0.166 0.313 0.992 0.184 0.965 1.005 0.187 0.968 1.004 0.185 0.966
‡
Unknown t0-status individuals.
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Table II. Results of the simulation studies showing the mean of the orretion terms. Means were
obtained from 1,000 independent samples.
Rate of Corretion term Corretion term
UKSI
‡ eC0(t0)† C1(t0)∗
Case 1 : λ = 100
0 1.000 1.053
5% 1.025 1.053
10% 1.053 1.054
20% 1.120 1.055
Case 2 : λ = 200
0 1.000 1.026
5% 1.026 1.026
10% 1.055 1.026
20% 1.124 1.027
Case 3 : λ = 400
0 1.000 1.013
5% 1.026 1.013
10% 1.055 1.013
20% 1.125 1.013
‡
Unknown t0-status individuals.
† eC0(t0) = Fn
ks
(t0)/Kn(t0).
∗C1(t0) = R2,n/R1,n.
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Table III. Coeients of the rst Rosner and Colditz model (RCM).
Parameter Regression oeient SE*
α (interept) -9.687 0.265
β0 (age at menarhe) 0.048 0.016
β1 (min[age, age at menopause℄ − age at menarhe) 0.081 0.004
β2 (age − age at menopause), for menopausal women 0.050 0.005
β3 (age at rst birth − age at menarhe) 0.013 0.004
β4 (birth index) -0.0036 0.0009
β5 (birth index × [age − age at menopause℄), for menopausal women -0.00020 0.00012
*SE: standard error.
Table IV. Evaluation of the alibration of the Rosner and Colditz 10-year risk of breast aner
predition tool. Results from the E3N ohort.
Population Rate of Observed Method Method Method Method
for validation UKSI
‡
Cases M0 M1 M2 M3
[CI*℄ [CI*℄ [CI*℄ [CI*℄
Whole sample 12.1% 2,765 0.889 0.932 0.940 0.947
[0.839-0.941℄ [0.880-0.987℄ [0.887-0.996℄ [0.912-0.982℄
Postmeno. Group 1
†
12.5% 1,160 0.635 0.672 0.678 0.682
[0.600-0.673℄ [0.634-0.711℄ [0.640-0.718℄ [0.644-0.721℄
Postmeno. Group 2
♮
51.5% 2,115 0.417 0.591 0.597 0.595
[0.394-0.442℄ [0.558-0.626℄ [0.564-0.633℄ [0.569-0.620℄
∗ CI : Condene intervals.
‡
Unknown t0-status individuals.
†
Postmenopausal women at inlusion.
♮
Postmenopausal women during follow-up.
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